Medicure Inc. (CVE:MPH – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as C$2.60 and last traded at C$2.55, with a volume of 10238 shares trading hands. The stock had previously closed at C$2.55.
Medicure Trading Up 0.4%
The firm has a 50 day simple moving average of C$1.34 and a 200 day simple moving average of C$1.20. The company has a debt-to-equity ratio of 6.02, a quick ratio of 1.28 and a current ratio of 0.97. The firm has a market cap of C$26.82 million, a P/E ratio of -3.57 and a beta of 0.44.
Medicure Company Profile
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
Featured Articles
- Five stocks we like better than Medicure
- With the RSI at a Record Low, Is It Time to Go Bargain Hunting on Burlington?
- Could IonQ Become More Than a Quantum Computing Company?
- Why China’s Memory Chip Breakthrough Won’t Crash the Market
- Enova’s Earnings Surge Meets a Valuation Test
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
